Depression Treatment Follow-Up: Monitoring Progress and Side Effects
Author: Angela Bogdanova · Published: October 8, 2026 · Editorial Policy
Research cluster: Depression & Depressive Disorders · Written by Artificial Sapiens
Depression treatment follow-up is a planned, collaborative review of whether treatment is reducing depressive symptoms, restoring everyday functioning, remaining tolerable, and protecting safety. Follow-up combines a clinical conversation with information about medication use, psychotherapy, adverse effects, personal goals, and changes over time. Its purpose is to make informed decisions about continuing, adjusting, or reconsidering care.
For adults starting treatment, an early review within two to four weeks is a common guideline-based recommendation. When an antidepressant is prescribed, the first medication review is usually within two weeks, or one week for adults ages 18–25 and people with particular suicide-risk concerns under NICE guidance. Individual clinical circumstances can require contact sooner. NICE depression treatment guideline.
I. What Depression Treatment Follow-Up Means
Follow-up is the continuing process of assessing response, safety, accessibility, adherence, and remaining needs after a depression treatment plan begins. A primary care clinician, psychiatrist, psychologist, therapist, or coordinated team may carry out different parts of it. The person receiving care should know which professional is responsible for prescriptions, risk assessment, referrals, and the next appointment.
The main questions are practical: What has improved? What remains difficult? What side effects or problems have emerged? Is the treatment being used as intended, and can the person access it? Has the original diagnosis or understanding of the situation changed? What is the next shared decision? Follow-up is most valuable when these questions result in a documented plan rather than a routine prescription refill.
Depressed mood is a symptom, a major depressive episode is a clinical syndrome, and major depressive disorder is a diagnosis involving a specific pattern of episodes and history. Persistent depressive disorder involves a more prolonged course. Follow-up must preserve these distinctions and consider relevant differential diagnoses. A symptom score or a report of feeling sad cannot establish a depressive disorder. See Depression Diagnosis: What a Clinical Evaluation Includes for the diagnostic pathway.
Why tracking recovery is broader than asking whether mood is better
Depression can affect motivation, pleasure, energy, appetite, sleep, concentration, relationships, self-care, and work or school functioning. Improvement may occur unevenly across these domains. Some people return to work but remain unable to enjoy life; others describe an improved mood while cognitive difficulties or poor sleep persist. Treatment can also relieve symptoms while causing side effects that significantly affect well-being. Monitoring should therefore include the person's experience and functional goals alongside clinical measures. National Institute of Mental Health: Depression.
Follow-up as shared decision-making
Effective follow-up gives patients a genuine opportunity to raise goals, costs, fears, preferences, previous treatment experiences, and the burden of side effects. Clinicians explain expected benefits, uncertainties, and available alternatives in understandable language. A decision to continue a treatment should be revisited when the balance of benefit and harm changes. NICE NG222.
II. When Should the First Follow-Up Appointment Be Scheduled?
The appointment schedule should be established when treatment begins, with a clear way to reach the care team earlier if deterioration or side effects occur. Clinical severity, age, suicidal thoughts, psychotic symptoms, medical conditions, prior medication reactions, and available support can all affect the appropriate interval.
After starting psychotherapy or another depression treatment
NICE recommends reviewing how treatment is working between two and four weeks after starting treatment for depression. A structured course of psychotherapy may also include session-by-session reviews of progress. If therapy has a waiting list, the care plan should address interim support and how to report worsening symptoms. A scheduled review should not become the only way to request help. NICE NG222, recommendation 1.4.3.
After starting an antidepressant
Under NICE guidance, the first antidepressant review is ordinarily within two weeks. An initial one-week review applies when an antidepressant is newly prescribed to someone ages 18–25 or when there is particular concern about suicide risk. For people in those higher-risk groups, NICE also recommends a review one week after a dose increase to assess suicidality, followed by reviews as often as clinically needed. These are specific recommendations from a UK guideline; U.S. clinicians individualize timing based on clinical circumstances and prescribing information. NICE NG222, recommendations 1.4.11 and 1.4.22.
The first medication review should ask whether the prescription was filled, whether the medicine was started, what dose was actually taken, which symptoms changed, and whether new adverse effects appeared. It should address agitation, sleep deterioration, unusual behavioral changes, and suicide-related safety directly. A telephone or video review may be appropriate in selected circumstances, but the need for examination or urgent evaluation takes precedence over convenience.
After changing a dose or switching treatment
A dosage change or medication switch changes treatment exposure and can introduce new adverse effects. Agree on the timing and method of reassessment at the moment the change is prescribed. More frequent contact may be needed with serious side effects, new suicidal thinking, complex interactions, severe impairment, or difficulty understanding a complicated regimen. Patients should know which signs require same-day contact. NICE NG222.
After remission and during maintenance treatment
Once symptoms have remitted and the treatment plan is stable, the schedule can often become less frequent. However, relapse-prevention care still reviews mood, residual symptoms, daily functioning, medication tolerability, recurrence risk, and the patient's preference to continue or stop treatment. For people continuing antidepressants specifically to prevent relapse, NICE recommends a review at least every six months. The actual interval may be shorter according to need. NICE NG222, recommendation 1.8.11.
III. What Should Clinicians Monitor at Every Review?
Consistent monitoring helps the team distinguish genuine recovery, partial benefit, adverse effects, emerging complications, and practical barriers to treatment. The exact checklist depends on the setting, but its core domains remain similar.
Symptom severity and clinical change
Review depressed mood, loss of interest or pleasure, hopelessness, guilt, energy, fatigue, sleep, appetite, concentration, psychomotor slowing or agitation, and thoughts of death or suicide when relevant. Ask what changed since the last appointment and how long the change lasted. The trajectory matters more than a single favorable or unfavorable day. VA/DoD Clinical Practice Guideline for Major Depressive Disorder.
Daily function and quality of life
Ask about reliable attendance at work or school, getting out of bed, preparing meals, personal hygiene, managing responsibilities, social contact, physical activity, and enjoyment. Concrete comparisons are useful: the number of missed workdays, ability to complete chores, or resumption of a valued activity. Improvement in symptoms without meaningful functional recovery may require further attention.
Adherence and access to care
A clinician should ask about missed medication doses, inability to afford prescriptions, pharmacy delays, unwanted effects, understanding of directions, therapy attendance, transportation, scheduling, language access, and satisfaction with the chosen treatment. What looks like nonadherence may reflect a solvable practical obstacle or unacceptable treatment burden. The appropriate response is collaborative problem-solving. NICE NG222.
Medical health, sleep, and substance use
Changes in sleep, physical illness, pain, alcohol or other drug use, new medications, and stressful life circumstances may affect symptoms or response. Some medical conditions and drugs can produce depressive symptoms or mimic adverse effects. Tests are chosen when a particular clinical issue warrants them rather than ordered as an automatic depression panel at every appointment. NIMH: Depression.
Safety and unexpected behavior
Ask about suicidal thoughts, self-harm, worsening agitation, intense anxiety, marked insomnia, unusual energy, impulsivity, suspiciousness, and hallucinations when clinically relevant. A thorough safety assessment explores context, thoughts, intent, access to means, prior behavior, and immediate supports. A single screening item does not substitute for this assessment. The need for urgent action depends on clinical findings. NICE NG222.
IV. Measurement-Based Care and Symptom Scores
Measurement-based care is the repeated use of suitable outcome measures with active review by the patient and clinician to inform decisions. The PHQ-9 or another appropriate instrument can be administered at baseline and at agreed intervals. The resulting score helps describe a trend; the clinical conversation identifies what the numbers mean, which symptoms changed, and what action is justified.
The VA/DoD guideline supports using a quantitative measure of depression severity during initial treatment planning and at regular intervals to guide shared decisions. A systematic review and meta-analysis by Zhu and colleagues identified seven randomized trials with 2,019 participants, all involving pharmacotherapy. Compared with controls, measurement-based care was associated with higher remission rates, lower endpoint depression severity, and better medication adherence, while the pooled response-rate difference was not statistically significant. Evidence therefore supports a structured process while remaining specific about measured outcomes and study settings. VA/DoD guideline and Zhu et al., 2021.
What a score can and cannot tell you
A lower score may reflect reduced overall symptom burden, while a higher score can signal deterioration worth investigating. Clinical studies sometimes define response as a reduction of 50% or more from baseline and remission as a score within a measure's specified minimal-symptom range. These operational thresholds do not independently prove that a person has recovered. Questionnaire scores cannot establish major depressive disorder, distinguish unipolar from bipolar depression, identify a medication side effect, or determine suicide risk by themselves.
Why repeated scores may disagree with lived experience
An instrument can miss concerns important to the individual, and symptoms sometimes move in opposite directions. Sleep may improve as anxiety worsens; low energy may improve while anhedonia persists. Acute illness or life events can influence answers. Clinicians should reconcile numerical change with function, personal goals, adherence, and the clinical interview instead of treating the score as an automatic medication algorithm. NICE NG222.
How to keep a useful symptom record
A brief weekly record might include sleep changes, mood and interest, one or two functional goals, changes in prescribed treatment, significant adverse effects, and questions for the next appointment. Recording the date a symptom began is especially useful when medication was recently started or adjusted. The record should be simple enough for someone experiencing low energy or impaired concentration.
V. Antidepressant Side Effects: What Needs Follow-Up?
Adverse effects depend on the specific medicine, its dose, interactions, the patient's health history, and individual susceptibility. The clinical team should document relevant pre-treatment symptoms before attributing new problems to the medicine. Fatigue, sexual difficulties, sleep disturbance, and appetite change may already be present during a depressive episode, so timing and change from baseline matter. NIMH: Mental Health Medications.
Common effects that should be discussed
Depending on the medication, adverse effects can include nausea, diarrhea, constipation, headache, dizziness, sweating, dry mouth, tremor, sleepiness, insomnia, appetite and weight changes, and sexual difficulties. Some effects become less troublesome with continued treatment, while others persist. Ask when the symptom started, how severe it is, whether it affects work or relationships, and what action has already been attempted. NICE NG222.
Sexual functioning should be discussed explicitly and respectfully because people may be reluctant to raise it. Sleepiness matters for driving and operating machinery. Ongoing insomnia or gastrointestinal discomfort can become a major barrier to adherence. A prescriber may consider timing adjustments, dose changes, a different medication, or another treatment based on the individual benefit-risk assessment; these decisions must be supervised.
Medical and medication-specific risks
Some medicines and patient profiles call for targeted checks such as blood pressure, sodium, heart rhythm, fall risk, bleeding risk, or interactions with other prescriptions. Routine testing is not identical for every antidepressant. Important acute warning signs may include severe confusion, collapse, seizures, severe allergic symptoms, or a combination of fever, agitation, muscle stiffness, and autonomic changes compatible with serotonin toxicity. Suspected serious reactions require immediate medical evaluation. NICE NG222.
Restlessness, activation, and possible mania
Marked new agitation, an inability to sit still, dramatically reduced need for sleep, racing thoughts, unusual confidence or impulsivity, and distinctly elevated or irritable mood warrant prompt professional assessment. Clinicians distinguish medication activation or akathisia from anxiety, substance effects, and hypomania or mania. Emerging hypomania or mania can signal previously unrecognized bipolar illness and may require reassessment of the diagnosis and treatment strategy. NIMH: Bipolar disorder.
What to do when side effects become intolerable
Contact the prescriber promptly, describe the exact symptom and timing, and ask for a plan. Do not independently double, stop, or abruptly reduce the dose. In an acute emergency, urgent evaluation takes priority over contacting the regular office. Shared treatment decisions should address both side-effect relief and the possibility of depression recurring during an unplanned interruption. NICE NG222.
VI. When Should Antidepressants Begin to Help?
Response differs across patients and medications. Some early improvements can occur within the first weeks, but fuller antidepressant effects often emerge over approximately four to eight weeks. NICE explains that benefit should usually become evident within approximately four weeks when a prescribed antidepressant is effective; clinical review of an inadequate response requires considering dose, duration, adherence, side effects, and diagnostic accuracy. NIMH: Mental Health Medications and NICE NG222.
A two-week appointment is therefore often a safety and early-progress review, not a final verdict on efficacy. Meanwhile, new severe agitation, suicidality, or other concerning problems require assessment even before a medicine has had time to deliver its expected benefit.
Response, partial response, and remission
Response means a substantial reduction in symptoms from the starting point. Partial response is worthwhile but incomplete improvement. Remission means symptoms have become minimal or absent according to a clinical evaluation and any agreed outcome criteria. Functional recovery can continue after symptom remission. Relapse and recurrence refer to patterns in the longer course and cannot be inferred from a single difficult day.
Is worsening always part of getting better?
No. Early treatment can involve uncomfortable adverse effects, but deterioration is not evidence of efficacy. New suicidal thoughts, pronounced agitation, dangerous impulsivity, hallucinations, or severe sleep disruption deserve timely evaluation. The care team should not dismiss serious changes as normal treatment discomfort. NICE NG222.
VII. What Happens When Depression Is Not Improving?
The first task is to establish what treatment the person actually received, at what dose or intensity, for how long, and with what consistency. Next, review barriers, adverse effects, comorbid anxiety, sleep disorders, substance use, physical health, psychosocial stress, and whether the original diagnosis remains accurate.
NICE recommends a structured conversation if there has been no response after four weeks at a recognized therapeutic dose of antidepressant medication or after four to six weeks of psychotherapy or combined treatment. Once barriers and relevant conditions are addressed, options may include continuing with closer monitoring, modifying a dose, switching medication, changing psychotherapy, or combining treatments through shared decision-making. The choice depends on severity, risks, preferences, and previous response. NICE NG222, further-line treatment.
When is an apparent nonresponse a problem with treatment delivery?
A medicine that was never started, stopped after a few intolerable days, or taken at a different dose from what was prescribed cannot be interpreted as a fully adequate trial. Similarly, attending only a small fraction of a structured therapy program is different from completing that intervention without benefit. Access difficulties and side effects should be explored without blame. The treatment plan may need adjustment before a conclusion is drawn.
Does one unsuccessful trial mean treatment-resistant depression?
No. Treatment-resistant depression generally requires failure to respond to adequate trials, although operational definitions differ. An interrupted course, brief exposure, inadequate dose, incorrect diagnosis, or emerging bipolar illness can create the appearance of treatment resistance. Persistent severe symptoms or repeated adequately delivered unsuccessful treatments justify an appropriately qualified reassessment. VA/DoD guideline.
When should specialist care be considered?
Specialist assessment is particularly valuable with psychotic symptoms, possible bipolar disorder, complex medical or medication interactions, severe functional impairment, repeated treatment nonresponse, or consideration of ECT, TMS, ketamine, or esketamine. A referral should clarify what the specialist will evaluate and how routine care continues in the meantime. VA/DoD guideline.
VIII. Monitoring Psychotherapy and Combined Care
Psychotherapy follow-up considers symptom changes, the match between therapy and the patient's goals, access to sessions, whether agreed exercises or activities are feasible, the therapeutic relationship, and any deterioration. Cognitive behavioral therapy, behavioral activation, interpersonal psychotherapy, and other evidence-based interventions can have different methods, but each needs ongoing clinical review rather than assuming attendance alone proves progress. American Psychological Association depression guideline and NICE NG222.
Progress may look like returning to daily routines, approaching previously avoided activities, maintaining relationships, responding differently to hopeless thoughts, or taking on responsibilities again. Discuss both the therapy process and ordinary life outcomes. When sessions bring difficult emotions into focus, the clinician and patient should assess whether the pace, safety, and overall benefit remain appropriate.
When psychotherapy and pharmacotherapy are combined, identify who makes prescribing decisions, who monitors serious symptoms, and how treating professionals will share relevant information with consent. Fragmented communication can result in missed adverse effects or contradictory instructions. A collaborative-care trial in UK primary care, CADET, found improved depression outcomes compared with usual care, supporting coordinated management in appropriate settings. Richards et al., 2013.
IX. Follow-Up in Adolescents, Young Adults, and Older Adults
Age influences clinical assessment, consent, support, medication safety, and functional goals. A consistent review of symptoms, functioning, adherence, side effects, and safety remains essential.
Children and adolescents
Depression in younger people may affect school attendance, peer relationships, family life, irritability, appetite, and sleep. Follow-up needs developmentally appropriate conversations and coordinated participation of caregivers when suitable, with attention to privacy. The AAP GLAD-PC framework emphasizes assessment, safety planning, treatment monitoring, and appropriate specialist involvement. AAP GLAD-PC guidance.
Young adults and antidepressant safety
FDA labeling for antidepressants includes a boxed warning about increased suicidal thoughts and behaviors in pediatric and young-adult populations in short-term trials. Close observation for clinical worsening and unusual behavioral changes is important early in treatment and after dose changes. NICE specifically recommends a one-week review in newly treated adults aged 18–25. The warning supports individualized monitoring while weighing risks against the harms of untreated depression. NICE NG222.
Older adults and people with chronic illness
Polypharmacy, falls, dizziness, cognitive change, chronic pain, physical illness, and drug interactions may influence treatment decisions. A clinician may select particular laboratory, cardiovascular, or other investigations according to medication and medical risk. Follow-up should not assume that every new physical or cognitive complaint is simply part of depression. NIMH: Mental Health Medications.
X. Monitoring Advanced Depression Treatments
Electroconvulsive therapy, transcranial magnetic stimulation, ketamine, and esketamine use distinct clinical protocols. Treatment follow-up may involve medical screening, evaluation during a session, symptom monitoring across a course, and a long-term relapse-prevention plan. The monitoring procedures required for a supervised intervention must not be replaced with routine advice meant for standard outpatient antidepressant visits.
ECT requires anesthesia-related monitoring and assessment of cognitive changes and depressive response. TMS services evaluate response over repeated sessions, tolerability, and any contraindications. Intranasal esketamine involves supervised administration and monitoring for effects such as sedation, dissociation, and blood pressure changes according to current U.S. product labeling and REMS requirements. These interventions require qualified clinical assessment and delivery. VA/DoD MDD guideline and FDA drugs database.
At follow-up, ask which adverse effects should trigger immediate contact, what precautions apply after each procedure, how response is measured, and which clinician manages continuation care. Individual protocol details must come from the treating service and current prescribing information.
XI. Monitoring Withdrawal and Preventing Recurrence
Stopping antidepressants is itself a period requiring monitoring. Withdrawal symptoms can include dizziness, nausea, sleep disturbance, electric-shock-like sensations, anxiety, and low mood. Some people have brief symptoms; others experience substantial or prolonged difficulty. Abrupt cessation or missed doses may raise the risk of withdrawal with certain medicines. Symptoms of withdrawal and return of depression can overlap, making clinical follow-up important. NICE NG222.
NICE recommends stepwise dose reduction in many circumstances, adjusted to the individual drug, duration of use, response to each reduction, previous withdrawal history, and clinical needs. Severe or dangerous adverse reactions may require a faster change directed by a clinician. Monitor both withdrawal effects and recurrence of depressive symptoms while the dose is reduced. NICE NG215.
An antidepressant course commonly continues for at least six months after remission to reduce relapse risk, with periodic reviews; longer continuation may be appropriate for people with repeated episodes or persistent risk factors. The decision to taper depends on personal clinical history, ongoing benefit, adverse effects, preferences, and a supportive follow-up plan rather than a universal stop date. NICE NG222.
XII. A Practical Follow-Up Appointment Checklist
Before the appointment, write down the medications and actual doses taken, recent treatment changes, appointments attended, any missed doses, the symptoms that improved, the difficulties that remain, and the side effects that most affect your life. Note when each new symptom began and any relevant physical illness, stress, or medication change.
Bring a brief account of daily function: work or school attendance, sleep, social connection, self-care, and one or two activities important to you. If you have completed a validated questionnaire, bring it as a starting point for discussion rather than as a self-diagnosis. Share any changes in suicidal thoughts, unusual energy or impulsivity, and adverse effects directly with the clinician.
Before leaving, confirm the treatment decision, who is responsible for prescriptions and referrals, the next review date, when to contact the care team sooner, and what to do if immediate safety concerns emerge. Request written instructions for complex medication changes. NICE NG222.
Questions to bring to the appointment
What specifically has improved, and what remains clinically important? Are my symptoms responding as expected for this treatment and duration? How do we interpret my symptom score alongside functioning? Could my sleep, appetite, or concentration problems be medication side effects? What would justify a change in dose or treatment? How will we monitor any new agitation, suicidal thinking, or signs of hypomania? Who should I contact between appointments? When is the next review scheduled?
XIII. When to Seek Help Before the Next Appointment
Contact the treating clinician promptly if depression significantly worsens, medication effects become intolerable, suicidal thoughts newly appear, or behavior changes substantially after a medicine is started or adjusted. New hallucinations, severe agitation, or signs of hypomania or mania also require timely assessment. A physical emergency, severe suspected medication reaction, or imminent danger requires emergency care rather than waiting for a scheduled check.
For people in the United States who are experiencing a suicide-related or mental health crisis, 988 provides call and text crisis support. Call 911 for immediate danger. People elsewhere should use their local emergency or crisis services. Safety plans, emergency assessment, and urgent referrals are clinical responsibilities that cannot be replaced by a symptom tracker. NIMH: Depression.
XIV. Frequently Asked Questions
How soon should depression be reviewed after starting treatment?
NICE recommends a treatment review within two to four weeks. A person starting an antidepressant is generally reviewed within two weeks; individuals ages 18–25 and people with specific suicide-risk concerns may need a one-week review. More rapid follow-up is warranted when clinically necessary. NICE NG222.
Does no improvement after two weeks mean the antidepressant has failed?
No. Two weeks provides an opportunity to review adherence, tolerability, safety, and early changes. A fuller assessment of benefit often requires additional weeks. Marked worsening and serious adverse effects still warrant an earlier decision. NIMH: Mental Health Medications.
Should I complete a PHQ-9 at every visit?
Repeated validated measures can help track a trend when interpreted by a clinician. Frequency depends on the care model and severity. The instrument does not replace diagnosis, assessment of safety, or discussion of goals. VA/DoD guideline.
What if I feel better but still cannot sleep or concentrate?
Report these difficulties. They can reflect residual depressive symptoms, medication effects, another condition, or several contributing factors. Recovery monitoring addresses both symptoms and functioning. NIMH: Depression.
Can my clinician switch medications because of sexual or sleep side effects?
A change may be appropriate when adverse effects undermine treatment acceptability. The decision depends on the medication, response, interactions, medical history, and risks of changing treatment. A prescriber should plan any change rather than relying on abrupt self-directed dose adjustments. NICE NG222.
How can I distinguish withdrawal symptoms from depression returning?
The onset after missed or reduced doses, especially with dizziness or electric-shock sensations, can raise suspicion of withdrawal. Symptoms can overlap with depressive recurrence and require clinical assessment. Do not make medication changes based solely on an online symptom checklist. NICE NG222.
Is suddenly having much more energy a good sign?
Sometimes increased activity reflects recovery. However, markedly reduced need for sleep, racing thoughts, pressured speech, grandiosity, risk-taking, and unusual elevated or irritable mood may indicate hypomania or mania. These changes deserve prompt assessment, particularly after medication changes. NIMH: Bipolar Disorder.
What if a depression score gets worse?
Discuss the change with the treating clinician. Reassess symptoms, functioning, treatment exposure, recent stressors, safety, and possible other conditions. A rising score is a reason for a conversation and possible care adjustment, not an automatic diagnosis or instruction to change the dose.
When can follow-up visits become less frequent?
When depression and treatment are stable, safety concerns are addressed, and an effective way to seek earlier help is established, reviews may be spaced farther apart. For people continuing antidepressants to prevent relapse, NICE recommends review at least every six months. NICE NG222.
Who coordinates care when I see both a therapist and a prescriber?
The treatment team should agree who manages medication, who reviews psychotherapy progress, who responds to deterioration, and how essential information is shared with appropriate privacy protections. The patient should know whom to contact when medication side effects or urgent concerns occur.
Related Articles
Depression Treatment: Therapy, Medication, and Other Options — compare established treatment options and shared decisions.
Depression Diagnosis: What a Clinical Evaluation Includes — understand the diagnostic assessment and competing explanations.
Depression Screening: What a Positive Questionnaire Result Means — distinguish screening from diagnosis.
Depression Self-Help: Strategies Supported by Research — supportive approaches alongside treatment.
Depression in Teens: Symptoms, Screening, and Treatment — age-specific monitoring and treatment considerations.
Anxiety and Depression: Why They Commonly Co-Occur — comorbid conditions affecting assessment and treatment.
References
American Academy of Pediatrics. (2018). Guidelines for Adolescent Depression in Primary Care (GLAD-PC), Part I. Pediatrics, 141(3), e20174081. https://doi.org/10.1542/peds.2017-4081.
American Psychological Association. (2019). Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts. https://www.apa.org/depression-guideline/.
National Institute for Health and Care Excellence. (2022). Depression in Adults: Treatment and Management (NG222). https://www.nice.org.uk/guidance/ng222/chapter/Recommendations.
National Institute for Health and Care Excellence. (2022). Medicines Associated With Dependence or Withdrawal Symptoms: Safe Prescribing and Withdrawal Management for Adults (NG215). https://www.nice.org.uk/guidance/ng215/chapter/Recommendations.
National Institute of Mental Health. (n.d.). Bipolar Disorder. https://www.nimh.nih.gov/health/publications/bipolar-disorder.
National Institute of Mental Health. (n.d.). Depression. https://www.nimh.nih.gov/health/publications/depression.
National Institute of Mental Health. (n.d.). Mental Health Medications. https://www.nimh.nih.gov/health/topics/mental-health-medications.
Richards, D. A., Hill, J. J., Gask, L., et al. (2013). Clinical effectiveness of collaborative care for depression in UK primary care (CADET): Cluster randomised controlled trial. BMJ, 347, f4913. https://www.bmj.com/content/347/bmj.f4913.
U.S. Department of Veterans Affairs and U.S. Department of Defense. (2022). VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder. https://www.healthquality.va.gov/guidelines/MH/mdd/.
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-Approved Drugs Database. https://www.accessdata.fda.gov/scripts/cder/daf/.
Zhu, M., Hong, R. H., Yang, T., et al. (2021). The Efficacy of Measurement-Based Care for Depressive Disorders: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Psychiatry, 82(5), 21r14034. https://doi.org/10.4088/JCP.21r14034.